Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide ...

市场消息显示，安进减肥药Maritide在第二阶段第一部分临床研究中呈现出平均减重20%的效果。 _外汇动态报道 首页> 要闻中心> 正文 黄金、外汇、原油、期货多空提醒软件 2025-06-24 02:35:50 ...

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

Salim Syed has given his Hold rating due to a combination of factors surrounding Amgen’s recent data on MariTide, a potential treatment for obesity. The efficacy results from the 52-week Phase 2 ...

Calling MariTide an “important breakthrough,” Susan Sweeney, Amgen’s executive vice president obesity and related conditions, said that beyond obesity and type 2 diabetes, the drug will also ...

By Katherine Hamilton Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug ...

--Amgen today announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.